Robert J. de Vaere

iVOW Inc, formerly Vista Medical Technologies, Inc. (VMTI) is a disease state management company focused on the treatment of morbid obesity. The company operates two business units: Obesity Surgical and Medical Management Services and Visualization Technology. The Obesity Surgical and Medical Management Services business, operated by the Company's wholly owned subsidiary, VOW Solutions, Inc., provides services to physicians and hospitals involved in the surgical treatment of morbid obesity. Its services include management of the Company's original product offering, the Laparoscopic Bariatric Surgery Preceptorship, an introduction to starting a minimally invasive gastric bypass surgical program. In addition, the business offers consulting and program management services, which enable the efficient operation of obesity surgery programs.

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Nexa Orthopedics, Inc. manufactures and markets devices for orthopedic and podiatric surgeons. It offers a line of implants, devices, and biologic products for surgeons. The company was founded in 2004 and is headquartered in San Diego, CA

IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA.

Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance.

Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL.